TICKERNERD
Menu
KODKODHealthcare · Biotechnology

KOD Stock Forecast: Kodiak Sciences, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$33
+0.06% on the day

The 6 Wall Street analysts covering Kodiak Sciences, Inc. hold a median 12-month price target of $69 — +109.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 12 Sept 2026 — in the lower half.

Market cap
$2.1B
Ticker Nerd rank
43 / 100
Median analyst target
$69
Analysts covering
6
Revenue$0.0
Operating income−$66.8M
Net income−$65.6M
Free cash flow−$46.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.5%
1M
−21.9%
YTD
+17.6%
1Y
+231.6%
From 52W high
−29.2%
From 52W low
+257.1%
$9
$46
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KOD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kodiak Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
43 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
90
Accruals
88
Issuance
68
Value
65
Size
36
Revisions
28
Growth
27
Quality
21
Volatility
17

Momentum (90): The shares have been drifting up relative to others.

Volatility (17): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KOD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KOD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Oct 25Jan 26Apr 26Jul 26KODHigh $85Median $69Low $56

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $56Median $69High $85

The green dot is the last close — the median target sits +109.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Aug 2026HC Wainwright & Co.ReiteratesBuy$58
3 Aug 2026JP MorganMaintainsOverweight—
3 Aug 2026JP MorganMaintainsOverweight$56 → $66
11 May 2026Chardan CapitalUpgradeBuy—
11 May 2026Chardan CapitalUpgradeBuy$14 → $61
27 Mar 2026HC Wainwright & Co.ReiteratesBuy—
27 Mar 2026UBSMaintainsBuy—
10 Feb 2026HC Wainwright & Co.ReiteratesBuy—
22 Jan 2026HC Wainwright & Co.MaintainsBuy—
7 Jan 2026UBSInitiatesBuy—
17 Nov 2025Chardan CapitalMaintainsNeutral—
17 Nov 2025HC Wainwright & Co.MaintainsBuy—
11 Nov 2025HC Wainwright & Co.UpgradeBuy—
24 Oct 2025JP MorganUpgradeOverweight—
23 Oct 2025LifeSci CapitalInitiatesOutperform—
6 Oct 2025Chardan CapitalMaintainsNeutral—
25 Sept 2025BarclaysUpgradeEqual-Weight—
22 Sept 2025JefferiesInitiatesBuy—
18 Aug 2025HC Wainwright & Co.MaintainsNeutral—
14 Aug 2025BarclaysMaintainsUnderweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KOD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

KOD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Kodiak Sciences, Inc. returned +231.6% against +17.5% for the S&P 500, dividends included.

KOD vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500Oct 25Jan 26Apr 26Jul 26KODS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KOD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
5
Fundamentals

Kodiak Sciences, Inc. (KOD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−7.6×

Cheaper than 92% of US stocks

Price / sales
—
Price / book
33.8×

Cheaper than 3% of US stocks

EV / EBITDA
−8.6×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−368.4%

Higher than 4% of US stocks

Return on assets
−60.4%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Kodiak Sciences, Inc. (KOD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Kodiak Sciences, Inc. has a market value of $2.1B and an enterprise value of $2.0B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$242.0M.

  • Diluted earnings per share, trailing twelve months: $−4.19.

  • Free cash flow in the twelve months to 30 June 2026: −$159.9M.

  • Shares outstanding: 62.8M.

  • Trailing P/E: −7.6×; forward P/E: −8.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Kodiak Sciences, Inc. employs 141 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

KOD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KODKodiak Sciences, Inc.$2.1B
43
ZBIOZenas BioPharma, Inc.$2.0B
26
AGIOAgios Pharmaceuticals, Inc.$2.0B
82
VCELVericel Corp.$1.9B
94
GENBGenerate Biomedicines, Inc.$2.0B
1
RAPPRapport Therapeutics, Inc.$2.0B
46
URGNUroGen Pharma Ltd.$2.1B
82

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kodiak Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KOD news & analysis

3 Small-Cap Biotechs With Binary Catalysts on the Calendar

MarketBeat · 13 Sept 2026neutral

MarketBeat highlights that small-cap biotech investors often hinge on single calendar dates—clinical trial readouts or FDA decisions—rather than quarterly earnings, since these companies typically burn cash for years without product revenue.

Why it matters — For Kodiak Sciences watchers, this underscores that key clinical or regulatory milestones can be decisive catalysts for the stock, given the company's small-cap biotech profile.

Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus

Zacks Investment Research · 14 Aug 2026neutral

Kodiak Sciences reported a wider-than-expected Q2 loss while advancing its pipeline, with Zenkuda moving toward regulatory submission and key clinical data anticipated later in 2026.

Why it matters — KOD watchers would care because the progress of Zenkuda toward regulatory submission and upcoming clinical data are pivotal milestones for the company's pipeline and potential future value.

KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema

Zacks Investment Research · 11 Aug 2026positive

Kodiak Sciences has initiated a global Phase III study of KSI-501 for diabetic macular edema, testing the drug's dual mechanism targeting IL-6 and VEGF for more durable disease control.

Why it matters — This late-stage study marks a key regulatory milestone for Kodiak's pipeline, offering potential for a differentiated DME treatment if the dual-target approach proves successful.

Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema

PRNewsWire · 10 Aug 2026positive

Kodiak Sciences announced that the first patients have been enrolled in the global Phase 3 ALTO trial evaluating KSI-501 in patients with diabetic macular edema. The trial is designed to demonstrate superiority of KSI-501 versus aflibercept.

Why it matters — This marks a key clinical milestone for Kodiak's lead candidate KSI-501, advancing toward a pivotal readout in the diabetic macular edema indication.

FAQ

Frequently asked questions about KOD stock

What is the KOD stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Kodiak Sciences, Inc. have a median 12-month price target of $69, with estimates ranging from $56 to $85. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KOD stock a buy right now?

Of the 6 analysts covering Kodiak Sciences, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kodiak Sciences, Inc. 43 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KOD?

As at 12 Sept 2026, Kodiak Sciences, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (90 of 100).

Will KOD stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +109.8% from the last close, and Ticker Nerd's factor model ranks Kodiak Sciences, Inc. 43 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KOD stock forecast for 2030?

No analyst covering Kodiak Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KOD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $56 to $85 over the next 12 months.

How has KOD stock performed over the past year?

Kodiak Sciences, Inc. returned +231.6% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kodiak Sciences, Inc. do?

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases.

What is the latest news on KOD?

The most recent item we track (MarketBeat, 13 Sept 2026): "3 Small-Cap Biotechs With Binary Catalysts on the Calendar". MarketBeat highlights that small-cap biotech investors often hinge on single calendar dates—clinical trial readouts or FDA decisions—rather than quarterly earnings, since these companies typically burn cash for years without product revenue.

Company

About Kodiak Sciences, Inc.

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases. The company works on treatments for conditions that affect the retina and can lead to vision loss, with a portfolio centered on ophthalmology and retinal vascular disorders. Its current programs include late-stage and earlier-stage candidates built around its proprietary Antibody Biopolymer Conjugate platform, which is designed to support the development of next-generation eye medicines. Kodiak Sciences Inc. serves the biopharmaceutical and ophthalmic research markets by advancing specialized therapeutics for diseases such as wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and diabetic retinopathy. Headquartered in Palo Alto, California, and founded in 2009, the company remains focused on researching, developing, and commercializing retina-directed medicines for patients and eye-care specialists.

CEO Dr. Victor Perlroth M.D. · 141 employees · United States · https://kodiak.com